T5O0 — bioXXmed AG Share News
0.000.00%
Last trade - 00:00- €1.07m
- €0.98m
- €0.02m
Brief: CytoTools says withdraws planned convertible bonds and pursues alternatives
Brief: Cytotools increases share capital
Brief: CytoTools: issue of a convertible bond and cash capital increase
Brief: Cytotools says Dermapro receives market approval in india
Brief: Cytotools says re-establishes patent protection for DermaPro
Brief: CytoTools AG: presents a revised strategy for the marketing of DermaPro
German stocks - Factors to watch on October 24
Brief: CytoTools unit DermaTools Biotech GmbH submits claim against the drug manufacturer
Brief: Cytotools: results from phase II/III trial for treatment of leg ulcers with DermaPro
Brief: Cytotools unit signs contracts for production with German manufacturer
Brief: Cytotools strengthens unit DermaTools Biotech GmbH through capital increase
Brief: Cytotools about the results of European Phase III study of diabetic foot
Brief: CytoTools says treatment of diabetic foot with Dermapro not confirmed
Brief: Cytotools says Indian regulatory authorities recommend approval of Dermapro
Brief: Cytotools successfully places capital increase
Brief: Cytotools announces positive results in interim evaluation of European ulcer cruris study
Brief: FDA confirms that Cytotools can now request for clinical trial of DermaPro in US
Brief: CytoTools: delay in approval of DermaPro in India
Brief: Cytotools to expand clinical development program for DermaPro in U.S.